News

Read our latest news, and find more about us and our portfolio companies.

2017/01/17
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans

Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman’s reproductive health and pregnancy, announced today the appointment of a new Chief Financial Officer, Timothy M. Adams. Mr. Adams will be located in the Company’s U.S. headquarters in Boston, Massachusetts, which is expected to employ finance, IR and clinical operation people and support ObsEva’s clinical-stage programs in uterine fibroids, endometriosis, Assisted Reproductive Technology and preterm labor.

2017/01/13
ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor

ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor - First-in-class orally active prostaglandin F2alpha receptor antagonist designed to safely control inflammation, uterine contractions, membrane ruptures and cervical changes that can result in preterm birth - Geneva, Switzerland, 13 January 2017 - ObsEva, a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman's reproductive health and pregnancy, announced today the completion of a Phase 1 single and multiple ascending dose study of OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2alpha, or PGF2alpha, receptor antagonist for the treatment of preterm labor in weeks 24 to 34 of pregnancy. ObsEva is developing OBE022 to safely control PGF2alpha-mediated inflammation, decreasing uterine contractions and preventing membrane ruptures and cervical changes, which are the key features of preterm labor resulting in preterm birth. The study evaluated the safety, tolerability and pharmacokinetics of OBE022 in healthy post-menopausal female volunteers after single doses of 10 to 1,300 mg and multiple doses between 100 and 1,000 mg/day over 7 consecutive days.

2017/01/05
ARTSaVIT Ltd. Completes $6.3 Million Series A Financing

YAVNE, Israel, January 5, 2016 - Israeli cancer apoptosis company ARTSaVIT LTD announced today that it has completed a $6.3 million Series A round of financing led by Arkin Bio Ventures and Pontifax, with participation of M Ventures, Carmel Innovation and Carmel - Haifa University Economic Corporation Ltd.

2016/12/08
Key Synaffix Patent Covering Glycan-Conjugated ADC Process Granted in the United States

AMSTERDAM, NETHERLANDS – December 8, 2016 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent that encompasses the entire GlycoConnect™ process used to prepare glycan-conjugated ADCs has been granted in the US (US 9,504,758 B2), further strengthening its IP portfolio.

2016/12/06
Asceneuron appoints J. Michael Ryan, M.D. as Chief Medical Officer

Lausanne, Switzerland, December 6, 2016 - Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, today announced the appointment of J. Michael Ryan, M.D. as Chief Medical Officer. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael brings extensive drug development expertise to Asceneuron. He will be responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.

2016/11/02
Artios Pharma Ltd: Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

**Strengthened Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy ** Cambridge, UK, 2 November 2016. Artios Pharma Ltd., a newly launched private company focussed on developing novel cancer treatments targeting the DNA Damage Response (DDR), today announces it has strengthened its management team with the appointment of Dr Simon Boulton as Vice President (VP) Science Strategy.

ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI

*Trial shows meaningful increase in pregnancy and live birth rates in patients treated with OBE001 ObsEva to proceed with a Phase 3 clinical trial in Europe* **Geneva, Switzerland, 24 October 2016** - ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that impact a woman's reproductive health and pregnancy, announced today the results of its IMPLANT clinical trial, a Phase 2 clinical trial of OBE001 (nolasiban) for the improvement of clinical pregnancy and live birth rates in women undergoing embryo transfer (ET) following in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The trial was designed to assess the safety and efficacy of a range of doses of OBE001, an oral oxytocin receptor antagonist, compared to placebo.

2016/10/20
Synaffix Enters into a Commercial License Agreement with ADC Therapeutics

**AMSTERDAM, NETHERLANDS – October 20, 2016 –** Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies. Under the terms of the agreement, ADC Therapeutics has been granted a single-target license for one of its preclinical programs and has also been granted an option to take a limited number of additional single-target licenses for potential future programs.

2016/10/17
ObsEva Announces Plans to Conduct Initial Public Offering in the United States

GENEVA, SWITZERLAND, 17 October, 2016 – ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that the Company plans to conduct an initial public offering in the United States.

2016/10/12
ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis

GENEVA, SWITZERLAND, 12 October, 2016 - ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced randomization of the first patient in its Phase 2b clinical study (EDELWEISS) of OBE2109 for the treatment of endometriosis. OBE2109 is a novel, orally administered, gonadotropin-releasing hormone (GnRH) antagonist that has been tested in more than 150 Japanese patients with endometriosis. In those Phase 2a studies, conducted by Kissei Pharmaceutical Co., Ltd. (Kissei), a dose-dependent suppression of estradiol was observed with treatment with OBE2109. In addition, patients reported significant reductions of endometriosis-associated pelvic pain, analgesic use and bleeding days.

2016/09/22
iOmx Therapeutics raises EUR 40 million in Series A round

**Martinsried / Munich, Germany, September 22, 2016** -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, today announced the closing of a Series A financing round totaling EUR 40 million. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and M Ventures.

2016/09/21
Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies

$33.2 Million Series A Financing from SV Life Sciences, M Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures to fund development of a DDR focussed pipeline **Cambridge, UK, 21 September 2016**. Artios Pharma Ltd., a new private company focussed on developing novel cancer treatments targeting the DNA Damage Response, was officially launched today following a successful fundraise of $33.2 million (£25 million) in a Series A financing from a strong syndicate of leading European and US life science investors led by SV Life Sciences. The investment will be used to build a high value pipeline of first-in-class DDR therapies targeted against cancer and to progress its lead programme, Pol-theta, into the clinic.

2016/09/19
Parkinson’s disease: Prexton Therapeutics completes phase 1 clinical trial

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

2016/07/20
Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million

BOSTON--(BUSINESS WIRE)-- Akili Interactive Labs, Inc. ("Akili"), a digital medicine company developing novel, non-pharmacological therapeutics and diagnostics for cognitive disorders, today announced an $11.9 million expansion of its recent Series B financing. *M Ventures, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States and Canada), and Amgen Ventures, the venture arm of Amgen, joined existing investors to bring the total Series B proceeds to $42.4 million. Akili will use the funds to support and expand clinical development of its clinical-stage products into new areas, with an expanded focus on neurodegeneration, and to build out its commercial infrastructure as Akili nears the market with its late-stage products. With the M Ventures and Amgen Ventures investments, Akili now has four relationships with major biopharma companies or their investment affiliates, including its existing partnership with Pfizer, Inc. and an investment from Shire Pharmaceuticals.

2016/07/20
Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board

AMSTERDAM, THE NETHERLANDS — Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.

2016/06/28
Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics

Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics 28 June 2016 Cambridge, UK - Storm Therapeutics, a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, has secured £12 million in series ‘A’ funding from Imperial Innovations, Cambridge Innovation Capital, M Ventures and Pfizer Venture Investments. Storm Therapeutics is based upon the ground-breaking work of its founders, Professor Tony Kouzarides and Professor Eric Miska, in the field of RNA epigenetics.

2016/04/04
Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing

Israeli cancer metabolism company Metabomed LTD. announced today that it has completed an extension of its Series A round from current and new investors bringing the total of its

2016/03/07
Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial

First clinical trial with an mGluR4 positive allosteric modulator, a first-in-class compound for treating Parkinson’s disease, will assess safety and tolerability.

2016/01/11
F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology.

2016/01/04
Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego

Padlock Therapeutics, a biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, today announced the appointment of Kerri Mowen, Ph.D., one of